Quotient Wealth Partners LLC Sells 599 Shares of Novo Nordisk A/S (NYSE:NVO)

Quotient Wealth Partners LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% in the 4th quarter, Holdings Channel reports. The firm owned 8,985 shares of the company’s stock after selling 599 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $773,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. WCM Investment Management LLC raised its position in shares of Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock worth $345,588,000 after acquiring an additional 40,475 shares during the last quarter. Advisory Resource Group increased its position in Novo Nordisk A/S by 61.1% during the 4th quarter. Advisory Resource Group now owns 11,985 shares of the company’s stock valued at $1,031,000 after purchasing an additional 4,544 shares during the period. Apollon Wealth Management LLC raised its holdings in Novo Nordisk A/S by 13.9% during the 4th quarter. Apollon Wealth Management LLC now owns 44,228 shares of the company’s stock worth $3,804,000 after purchasing an additional 5,393 shares during the last quarter. Quattro Financial Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $299,000. Finally, Platform Technology Partners boosted its stake in shares of Novo Nordisk A/S by 38.7% in the 4th quarter. Platform Technology Partners now owns 5,677 shares of the company’s stock valued at $488,000 after purchasing an additional 1,584 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.9 %

NYSE NVO opened at $86.39 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The business has a 50 day moving average price of $91.46 and a 200-day moving average price of $111.51. The company has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Analysts Set New Price Targets

Several research firms recently issued reports on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.